Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-22-Speech-3-207"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-09-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"ro"^^xsd:language2
lpv:document identification number	"en.20100922.20.3-207"2
lpv:hasSubsequent	lp_eu:2010-09-22-Speech-3-2082
lpv:speaker	lp:Rovana Plumb2
lpv:spokenAs	member; EMPL (2009-07-16--2012-01-18)3 substitute; ENVI (2009-07-16--2012-01-18)3 substitute; Delegation to the Euronest Parliamentary Assembly (2010-05-04--2012-05-06)3 substitute; FEMM (2009-07-16--2012-01-18)3 unknown; Partidul Social Democrat (2009-07-14--2012-05-06)3 member; S&D (2009-07-14--2011-05-25)3 substitute; Delegation to the EU-Moldova Parliamentary Cooperation Committee (2009-09-16--2012-05-06)3 member; Delegation to the EU-Turkey Joint Parliamentary Committee (2009-09-16--2012-05-06)3
lpv:translated text	"Pharmacovigilance is the system used to monitor the safety of medicines after they have been authorised for public use. Under current EU legislation, medicines can be authorised in two ways: a) through a central procedure where an application is made by a pharmaceutical company to the EMEA (European Medicines Agency), or b) through a system of mutual recognition where one country leads on the assessment of the new drug and coordinates with other Member States through mutual recognition. Rules governing the procedure for the decentralised system are set out in Directive 2001/83/EC. I voted for this report as European patients will be better protected and informed about the use of medicines and their adverse effects. The new regulations provide for the creation of national and European websites, specifically for medicines, which can offer patients more information. The latter will have the opportunity to inform the national authorities about the drugs’ adverse effects."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph